Inhibikase Therapeutics, Inc. (IKT) — Operating Cash Flow
| Fiscal Year | Operating Cash Flow | Change YoY |
|---|---|---|
| 2025 | -$27.79M | -45.1% |
| 2024 | -$19.15M | -5.9% |
| 2023 | -$18.09M | -4.2% |
| 2022 | -$17.35M | -21.4% |
| 2021 | -$14.30M | -1165.9% |
| 2020 | -$1.13M | — |
| Fiscal Year | Operating Cash Flow | Change YoY |
|---|---|---|
| 2025 | -$27.79M | -45.1% |
| 2024 | -$19.15M | -5.9% |
| 2023 | -$18.09M | -4.2% |
| 2022 | -$17.35M | -21.4% |
| 2021 | -$14.30M | -1165.9% |
| 2020 | -$1.13M | — |